Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q2 2023 · 10-Q
Revenue$43.00K$43.00K−95.6% vs Q2 2022 Net Income-$3.42M-$3.42MN/M vs Q2 2022 EPS, diluted—
Operating Income-$3,452,000N/M Operating Cash Flowderived-$3,151,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,153,000N/M Margins · derivedOperating margin-8027.9%−7771.6 pt vs Q2 2022
Net margin-7962.8%−7706.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end